(Q37396205)

English

Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels

scientific article published on October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

cervical squamous cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Xiugui Sheng

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Xuelian Du

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Xiaoling Zhang

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Dapeng Li

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Chunhua Lu

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Qinshui Li

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Zhifang Ma

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Quqing Song

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Cong Wang

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Croatian Medical Journal

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

50

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

455-464

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Masquerader: high mobility group box-1 and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Studies reporting ROC curves of diagnostic and prediction data can be incorporated into meta-analyses using corresponding odds ratios

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

HMGB1: guiding immunity from within

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Cervical cancer staging.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Cancer burden in the year 2000. The global picture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

6 September 2017

Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

14 September 2017

Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

14 September 2017

HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

14 September 2017

Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

28 September 2017

Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

26 June 2018

Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

26 June 2018

[Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

2 September 2018

Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

2 September 2018

CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

2 September 2018

The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

2 September 2018

Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

2 September 2018

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765737

2 September 2018

Cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective Evaluation of Squamous Cell Carcinoma and Carcinoembryonic Antigen as Prognostic Factors in Patients with Cervical Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Posttherapy surveillance of women with cervical cancer: an outcomes analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19839069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3325/CMJ.2009.50.455

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37396205&oldid=2167463921"